NEW YORK, June 4, 2026, 12:03 (EDT)
NewcelX Ltd. shares were slightly up in midday Nasdaq action Thursday, with traders watching the Swiss biotech ahead of its late-June meeting with U.S. regulators on its main cell therapy for type 1 diabetes.
The shares traded at $3.18 by 11:47 a.m. EDT, up 2 cents, or 0.6% from the previous close. The session’s range so far has been $3.04 to $3.18. Volume was 13,288 shares at last check.
NewcelX is still in the clinic, so any regulatory step tends to matter more than shifts in quarterly sales. The pre-IND meeting is an early FDA check-in that happens before a company asks to run human trials. At this stage, the sponsor can get feedback on its preclinical work, plans for the first human trial, and production controls.
The move came as the rest of the market was mixed. Reuters said the Nasdaq Composite dropped 0.8% in the morning, with chip stocks under pressure after Broadcom missed on revenue. Healthcare names led S&P 500 gainers.
NewcelX said in a May 27 SEC filing that it has sent the FDA its pre-IND briefing materials for NCEL-101, its candidate made from stem cells, aiming for a first-in-human trial in type 1 diabetes. The meeting with regulators is set for the last week of June. Topics on the agenda include how the company makes NCEL-101, results from preclinical safety tests and plans for the clinical trial design.
NewcelX executive chairman and CEO Ronen Twito called the meeting “a pivotal milestone” for NCEL-101. Back in April, after NewcelX posted its 2025 results, Twito said he expected 2026 would see “significantly accelerated execution.” GlobeNewswire
NCEL-101 aims to replace the insulin-producing islet cells lost in type 1 diabetes. NewcelX plans to use it with tegoprubart from Eledon Pharmaceuticals, an immune-modulating drug in testing that could help limit transplant rejection. According to the company’s 20-F, Eledon has the option to end the collaboration with 30 days’ notice, which investors may want to note.
Competition is tough. Vertex Pharmaceuticals stood out last year when it said 10 of 12 patients on a full dose of zimislecel didn’t need outside insulin after 12 months. The treatment also needs ongoing immune-suppressing drugs. Vertex Chief Medical Officer Carmen Bozic called the data “unprecedented.” Vertex Pharmaceuticals Newsroom
NewcelX ended Dec. 31 with $2.2 million in cash and cash equivalents. For 2025, the company had a net loss of $8.3 million. In April, NewcelX raised $1.35 million in a private placement. The company also has possible warrant proceeds ahead and can tap a $25 million equity line, a setup that lets NewcelX raise funds by selling shares bit by bit.
The runway could tighten if the FDA wants more data, manufacturing hits delays, or if NewcelX ends up raising money on dilutive terms. The company said in its annual report that its current cash won’t cover operating needs for a year after the financial statement date. That raises “substantial doubt” about its ability to keep going. SEC
Shares barely moved today, but the next big update could matter more. Investors are still watching for June FDA feedback to see if NewcelX gets a smoother path to start human trials, or if it’s back to cash questions, warrants, and waiting for trial dates.
